Delivery Order 75N91019D00024-75N91026F00033

Award Date 9/25/26

Potential Completion Date 9/24/29

Potential Value $12M

Funding Federal Agency

National Institute of Allergy and Infectious Diseases

Contracting Federal Agency

National Cancer Institute

Awardee

Leidos Biomedical Research Inc. HV8BH9BPG8Y9

Ultimate Awardee

Leidos Holdings, Inc. ZL41ERXMPAR3

NAICS Category

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

PSC Category

AN12 - Health R&D Services; Health Care Services; Applied Research

Set-Aside Type

No Set-Aside Used

Federal Contract Vehicle

Not listed

Extent Competed

Full and Open Competition

Major Defense Program

Not listed

Pricing Type

Cost Plus Fixed Fee

Place of Performance

Frederick, MD 21702, USA

Solicitation Procedures

Negotiated Proposal / Quote

Number Of Offers Received

Not listed

Legislative Mandate

Service Contract Inventory

National Interest Action

Not listed

Research Type

Not listed

Primary Consortia Member

Not listed

The National Institute of Allergy and Infectious Diseases issued a delivery order to Leidos Biomedical Research Inc. on September 25, 2026, with a ceiling value of $11.7 million for an observational study of the natural history of Bundibugyo virus disease under cost-plus-fixed-fee pricing.

Place of performance is Frederick, Maryland. The order is set to complete by September 24, 2029. Leidos Biomedical Research operates as an FFRDC contractor delivering biomedical research and facilities support to the National Institutes of Health, with this work falling under its broader NIAID master indefinite delivery vehicle. The contractor maintains a stable workforce of approximately 1,830 FTEs and engages a multi-vendor network of subcontractors spanning academic institutions, diagnostic firms, laboratory equipment providers, and specialized research partners including Abbott Molecular Inc., University of Pittsburgh, and Stanford University.

Generated 9/29/26, 11:02 AM